Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis

Susan I. O'Shea, Jeffrey H. Lawson, Donal Reddan, Michael Murphy, Thomas L. Ortel

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Vascular access site thrombosis is a major cause of morbidity in patients receiving hemodialysis. The role of hypercoagulable states in recurrent vascular access site thrombosis remains poorly understood. Data are limited regarding systemic anticoagulation to improve access graft patency, because of concern about hemorrhagic complications. We determined the prevalence of hypercoagulable states and clinical outcome (thrombotic and hemorrhagic) after initiation of antithrombotic therapy in a series of patients with recurrent vascular access site thrombosis. We evaluated 31 patients who had sustained 119 thrombotic events that resulted in vascular access graft failure during the year before evaluation. Sixty-eight percent of patients tested had elevated concentrations of antibody to anticardiolipin or topical bovine thrombin, and 18% of patients tested had heparin-induced antibodies. More than 90% of patients had elevated factor VIII concentration, 62% had elevated fibrinogen concentrations, and 42% had elevated C-reactive protein concentrations. Twenty-nine patients were given antithrombotic therapy: 13 with warfarin sodium, 12 with unfractionated heparin (UFH), and 11 with low molecular weight heparin (LMWH). Seven patients received more than one antithrombotic agent, sequentially. Nineteen patients have had no thrombotic events since beginning antithrombotic therapy (10 with warfarin, 3 with UFH, 6 with LMWH). Mean follow-up was 8.6 months (median, 7 months). Eight patients sustained 10 bleeding complications (5 with warfarin, 3 with UFH, and 2 with LMWH). In conclusion, hypercoagulable states are common in patients with recurrent vascular access site thrombosis. Antithrombotic therapy may increase vascular access graft patency, but is associated with significant risk for hemorrhage. Prospective studies are needed to evaluate the role and safety of antithrombotic agents in improving vascular access graft patency.

Original languageEnglish (US)
Pages (from-to)541-548
Number of pages8
JournalJournal of Vascular Surgery
Volume38
Issue number3
DOIs
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

Blood Vessels
Thrombosis
Heparin
Low Molecular Weight Heparin
Warfarin
Transplants
Fibrinolytic Agents
Hemorrhage
Anticardiolipin Antibodies
Factor VIII
Therapeutics
Thrombin
C-Reactive Protein
Fibrinogen
Renal Dialysis
Prospective Studies
Morbidity
Safety
Antibodies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. / O'Shea, Susan I.; Lawson, Jeffrey H.; Reddan, Donal; Murphy, Michael; Ortel, Thomas L.

In: Journal of Vascular Surgery, Vol. 38, No. 3, 09.2003, p. 541-548.

Research output: Contribution to journalArticle

O'Shea, Susan I. ; Lawson, Jeffrey H. ; Reddan, Donal ; Murphy, Michael ; Ortel, Thomas L. / Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. In: Journal of Vascular Surgery. 2003 ; Vol. 38, No. 3. pp. 541-548.
@article{35c428c8a1ab4aef9b050c3700686bd6,
title = "Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis",
abstract = "Vascular access site thrombosis is a major cause of morbidity in patients receiving hemodialysis. The role of hypercoagulable states in recurrent vascular access site thrombosis remains poorly understood. Data are limited regarding systemic anticoagulation to improve access graft patency, because of concern about hemorrhagic complications. We determined the prevalence of hypercoagulable states and clinical outcome (thrombotic and hemorrhagic) after initiation of antithrombotic therapy in a series of patients with recurrent vascular access site thrombosis. We evaluated 31 patients who had sustained 119 thrombotic events that resulted in vascular access graft failure during the year before evaluation. Sixty-eight percent of patients tested had elevated concentrations of antibody to anticardiolipin or topical bovine thrombin, and 18{\%} of patients tested had heparin-induced antibodies. More than 90{\%} of patients had elevated factor VIII concentration, 62{\%} had elevated fibrinogen concentrations, and 42{\%} had elevated C-reactive protein concentrations. Twenty-nine patients were given antithrombotic therapy: 13 with warfarin sodium, 12 with unfractionated heparin (UFH), and 11 with low molecular weight heparin (LMWH). Seven patients received more than one antithrombotic agent, sequentially. Nineteen patients have had no thrombotic events since beginning antithrombotic therapy (10 with warfarin, 3 with UFH, 6 with LMWH). Mean follow-up was 8.6 months (median, 7 months). Eight patients sustained 10 bleeding complications (5 with warfarin, 3 with UFH, and 2 with LMWH). In conclusion, hypercoagulable states are common in patients with recurrent vascular access site thrombosis. Antithrombotic therapy may increase vascular access graft patency, but is associated with significant risk for hemorrhage. Prospective studies are needed to evaluate the role and safety of antithrombotic agents in improving vascular access graft patency.",
author = "O'Shea, {Susan I.} and Lawson, {Jeffrey H.} and Donal Reddan and Michael Murphy and Ortel, {Thomas L.}",
year = "2003",
month = "9",
doi = "10.1016/S0741-5214(03)00321-5",
language = "English (US)",
volume = "38",
pages = "541--548",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis

AU - O'Shea, Susan I.

AU - Lawson, Jeffrey H.

AU - Reddan, Donal

AU - Murphy, Michael

AU - Ortel, Thomas L.

PY - 2003/9

Y1 - 2003/9

N2 - Vascular access site thrombosis is a major cause of morbidity in patients receiving hemodialysis. The role of hypercoagulable states in recurrent vascular access site thrombosis remains poorly understood. Data are limited regarding systemic anticoagulation to improve access graft patency, because of concern about hemorrhagic complications. We determined the prevalence of hypercoagulable states and clinical outcome (thrombotic and hemorrhagic) after initiation of antithrombotic therapy in a series of patients with recurrent vascular access site thrombosis. We evaluated 31 patients who had sustained 119 thrombotic events that resulted in vascular access graft failure during the year before evaluation. Sixty-eight percent of patients tested had elevated concentrations of antibody to anticardiolipin or topical bovine thrombin, and 18% of patients tested had heparin-induced antibodies. More than 90% of patients had elevated factor VIII concentration, 62% had elevated fibrinogen concentrations, and 42% had elevated C-reactive protein concentrations. Twenty-nine patients were given antithrombotic therapy: 13 with warfarin sodium, 12 with unfractionated heparin (UFH), and 11 with low molecular weight heparin (LMWH). Seven patients received more than one antithrombotic agent, sequentially. Nineteen patients have had no thrombotic events since beginning antithrombotic therapy (10 with warfarin, 3 with UFH, 6 with LMWH). Mean follow-up was 8.6 months (median, 7 months). Eight patients sustained 10 bleeding complications (5 with warfarin, 3 with UFH, and 2 with LMWH). In conclusion, hypercoagulable states are common in patients with recurrent vascular access site thrombosis. Antithrombotic therapy may increase vascular access graft patency, but is associated with significant risk for hemorrhage. Prospective studies are needed to evaluate the role and safety of antithrombotic agents in improving vascular access graft patency.

AB - Vascular access site thrombosis is a major cause of morbidity in patients receiving hemodialysis. The role of hypercoagulable states in recurrent vascular access site thrombosis remains poorly understood. Data are limited regarding systemic anticoagulation to improve access graft patency, because of concern about hemorrhagic complications. We determined the prevalence of hypercoagulable states and clinical outcome (thrombotic and hemorrhagic) after initiation of antithrombotic therapy in a series of patients with recurrent vascular access site thrombosis. We evaluated 31 patients who had sustained 119 thrombotic events that resulted in vascular access graft failure during the year before evaluation. Sixty-eight percent of patients tested had elevated concentrations of antibody to anticardiolipin or topical bovine thrombin, and 18% of patients tested had heparin-induced antibodies. More than 90% of patients had elevated factor VIII concentration, 62% had elevated fibrinogen concentrations, and 42% had elevated C-reactive protein concentrations. Twenty-nine patients were given antithrombotic therapy: 13 with warfarin sodium, 12 with unfractionated heparin (UFH), and 11 with low molecular weight heparin (LMWH). Seven patients received more than one antithrombotic agent, sequentially. Nineteen patients have had no thrombotic events since beginning antithrombotic therapy (10 with warfarin, 3 with UFH, 6 with LMWH). Mean follow-up was 8.6 months (median, 7 months). Eight patients sustained 10 bleeding complications (5 with warfarin, 3 with UFH, and 2 with LMWH). In conclusion, hypercoagulable states are common in patients with recurrent vascular access site thrombosis. Antithrombotic therapy may increase vascular access graft patency, but is associated with significant risk for hemorrhage. Prospective studies are needed to evaluate the role and safety of antithrombotic agents in improving vascular access graft patency.

UR - http://www.scopus.com/inward/record.url?scp=0141501076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141501076&partnerID=8YFLogxK

U2 - 10.1016/S0741-5214(03)00321-5

DO - 10.1016/S0741-5214(03)00321-5

M3 - Article

C2 - 12947274

AN - SCOPUS:0141501076

VL - 38

SP - 541

EP - 548

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 3

ER -